ARTV Stock Summary and Trading Ideas (Artiva Biotherapeutics | NASDAQ:ARTV)

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Artiva Biotherapeutics trades on the NASDAQ stock market under the symbol ARTV.

As of March 4, 2026, ARTV stock price declined to $5.46 with 75,834 million shares trading.

ARTV has a beta of 1.44, meaning it tends to be more sensitive to market movements. ARTV has a correlation of 0.03 to the broad based SPY ETF.

ARTV has a market cap of $134.02 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that ARTV belongs to (by Net Assets): VTI, VXF, IWC, DCOR, DFAS.

ARTV has outperformed the market in the last year with a price return of +39.3% while the SPY ETF gained +18.6%. ARTV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +52.5% and +32.8%, respectively, while the SPY returned +0.5% and +0.3%, respectively.

ARTV support price is $5.14 and resistance is $5.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARTV shares will trade within this expected range on the day.